The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Publications
Koyama N, Iwase O, Nakashima E, Kishida K, Kondo T, Watanabe Y, Takahashi H, Umebayashi Y, Ogawa Y, Miura H
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
BMC pulmonary medicine 2018 Jan 30;18;23 — 2018 Jan 30 — 23
Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Pharmacotherapy 2017 Nov;37;1383-1390 — 2017 Nov — 1383-1390
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Le
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
The European respiratory journal 2017 08;50; — 2017 08
Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Dec 15;22;6051-6060 — 2016 Dec 15 — 6051-6060
Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS, Awad MM
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Cancer immunology research 2016 Apr;4;289-93 — 2016 Apr — 289-93
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The New England journal of medicine 2015 May 21;372;2006-17 — 2015 May 21 — 2006-17
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lope
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
The Lancet. Oncology 2015 Mar;16;257-65 — 2015 Mar — 257-65
Checkpoint blocking antibodies in cancer immunotherapy.
FEBS letters 2014 Jan 21;588;368-76 — 2014 Jan 21 — 368-76
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
The New England journal of medicine 2013 Jul 11;369;134-44 — 2013 Jul 11 — 134-44
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013;; — 2013
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
The New England journal of medicine 2012 Jun 28;366;2443-54 — 2012 Jun 28 — 2443-54